![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Evaluation of: Ivanova JI, Birnbaum HG, Kidolezi Y et al. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 28(8), 675–685 (2010).
Epilepsy is a chronic condition characterized by recurrent unprovoked seizures. Epilepsy is typically treated with antiepileptic drugs, although surgery is superior to medical therapy for those who are resistant to medications, and is more more cost effective when successful. The discussion article examines the direct medical costs of epilepsy and the rate of medically related absenteeism compared with a matched control group in the USA. Individuals with epilepsy were found to have significantly higher medical costs and more short- and long-term disability days. This article demonstrates that claims data can be used to assess the indirect impact of epilepsy on employment; however, the addition of other datasets is necessary to more comprehensively assess the impact of epilepsy on employment-related outcomes.
Financial and competing interests disclosure
Nathalie Jette holds salary awards from the Canadian Institutes of Health Research (CIHR; Ottawa, Canada) and Alberta Innovates Health Solutions (AI-HS; Alberta, Canada). Amy Metcalfe holds a CIHR doctoral award in Genetics (Ethics, Law and Society) and a CIHR studentship in Genes, Development and Child Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.